Breaks Categories: News

WednesdayFeb 05, 2025 11:56 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development

Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five years. The company plans to use the funds primarily for the continued Phase 3 development of its lead Alzheimer’s drug, Buntanetap, as well as for working capital and corporate purposes. ThinkEquity acted as the sole book-running manager. To view the full press release, visit https://ibn.fm/rOYgn…

Continue Reading

TuesdayFeb 04, 2025 3:07 pm

BioMedNewsBreaks — BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT) Announces Pricing of $3.05M Public Offering

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announced the pricing of a best-efforts public offering of 762,500 common shares, each at a public offering price of $4.00. The company expects $3.05 million in total gross proceeds from the offering, of which it intends to use the net for working capital, general corporate purposes, and the advancement of business objectives. Subject to the satisfaction of customary conditions, the offering is expected to close on Feb. 5, 2025. ThinkEquity is acting as the sole placement agent for the offering. To…

Continue Reading

TuesdayFeb 04, 2025 10:46 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Positive Clinical Trial Results for unbuzzd™

Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd™, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd™ lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing heart rate and blood pressure. Participants also reported reduced mental fatigue and hangover symptoms without adverse side effects. Quantum BioPharma CEO Zeeshan Saeed highlighted unbuzzd™ as a breakthrough in promoting safe and responsible alcohol consumption. To view the full press release, visit https://ibn.fm/jKWGf About Quantum…

Continue Reading

TuesdayFeb 04, 2025 9:50 am

BioMedNewsBreaks – HealthLynked Corp. Highlights 2024 Achievements, Sets Vision for Future Growth

HealthLynked (OTCQB: HLYK) released its Annual Shareholder Letter, detailing key advancements in 2024 and outlining its strategic priorities for 2025. The company launched ARI, an AI-powered healthcare guidance tool, expanded its telemedicine services nationwide, introduced a concierge healthcare service, and implemented a discount prescription drug program. CEO Dr. Dent emphasized HealthLynked’s focus on scaling its platform through strategic partnerships, innovative marketing, and expanded service offerings. Looking ahead, the company aims to enhance patient care management, broaden healthcare access, and leverage patient data for medical research and improved outcomes. To view the full press release, visit https://ibn.fm/RttDI About HealthLynked Corp. HealthLynked…

Continue Reading

MondayFeb 03, 2025 11:29 am

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) Announces Board Appointment of Visionary Leader Mark Frissora

BioAdaptives (OTC: BDPT), a pioneering health and wellness company dedicated to innovative, science-driven solutions, has announced the appointment of Mark Frissora to its board of directors. An acclaimed business leader, Frissora is celebrated for transforming global brands and driving extraordinary growth at Fortune 500 companies such as Hertz and Caesars Entertainment. “Mark’s exceptional track record in revitalizing global brands and his deep expertise in operational excellence make him an invaluable asset,” said James Keener, CEO of BioAdaptives. “His accomplishments speak for themselves, and we are excited to benefit from his insights as we pursue groundbreaking solutions that enhance lives through…

Continue Reading

MondayFeb 03, 2025 8:55 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing treatments for neurodegenerative diseases, has priced an underwritten public offering of 5.25 million shares of common stock and warrants at a combined price of $4 per share. The warrants, exercisable at $5 per share for five years, are expected to generate gross proceeds of $21 million before deducting expenses. ThinkEquity is the sole book-running manager. The offering is set to close Feb. 4, 2025, subject to customary conditions, with proceeds primarily allocated to working capital and further clinical development of its lead drug candidate, Buntanetap. To view the full…

Continue Reading

WednesdayJan 29, 2025 10:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software

HeartBeam (NASDAQ: BEAT), a medical technology company advancing cardiac care, has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram (“ECG”) synthesis software. The software is designed to assess cardiac rhythms and arrhythmias, including atrial fibrillation, atrial flutter, bradycardia, and tachycardia. The submission is supported by data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites and demonstrated clinical equivalence to standard 12-lead ECGs. HeartBeam recently secured FDA clearance for its patented technology that captures heart signals from three directions and synthesizes them into a traditional 12-lead ECG format.…

Continue Reading

WednesdayJan 29, 2025 9:55 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar on Feb. 5

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an investor webinar on Feb. 5, 2025, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD, PhD, discussing Calidi’s cell-based delivery platforms designed to enhance oncolytic virus-based cancer treatments. Topics will include the company’s lead programs, such as CLD-400 for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade glioma. A live Q&A session will follow. To view the full press release, visit: https://ibn.fm/IXjhS About Calidi Biotherapeutics Calidi Biotherapeutics specializes in…

Continue Reading

TuesdayJan 28, 2025 9:58 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Ends SEPA Agreement Following Successful Fundraising

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a cash balance of approximately $9.6 million as of Dec. 31, 2024, and announced the termination of its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., effective Jan. 23, 2025. Calidi secured $9.5 million in gross proceeds in late 2024 through public offerings, $2.0 million from warrant exercises, and $3.1 million via its At-The-Market Offering Agreement ("ATM"), alongside $4.25 million raised in January 2025. CEO Allan Camaisa emphasized the move as a strategic step to enhance shareholder value and focus on advancing its…

Continue Reading

TuesdayJan 21, 2025 3:21 pm

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) Announces Dividend for Common Stock Shareholders

BioAdaptives (OTC: BDPT), a forward-thinking innovator in health and wellness solutions, today announced that FINRA has approved a dividend to its common stock shareholders. The decision reflects the company’s gratitude for the unwavering support of its shareholders and their confidence in BioAdaptives’ mission and growth trajectory. “This dividend is a heartfelt thank you to our shareholders who have stood by us through our journey,” said James Keener, CEO of BioAdaptives. “Your confidence in our vision to revolutionize health and wellness has been integral to our progress. This gesture underscores our appreciation and reaffirms our commitment to delivering long-term value as…

Continue Reading